Advanced glycation end products in diabetes, cancer and phytochemical therapy.

Abstract:

:The irreversible glycation and oxidation of proteins and lipids produces advanced glycation end products (AGEs). These modified AGEs are triggered to bind the receptor for AGE (RAGE), thereby activating its downstream signaling pathways, such as nuclear factor (NF)-κB and phosphoinositide 3-kinase (PI3K)/Akt, ultimately leading to diabetes and cancers. In this review, we focus on the interaction of AGE-RAGE and their associated pathways. We also consider the activity of phytochemicals, such as genistein and curcumin, that trap dicarbonyl compounds including methylglyoxal (MG) and glyoxalase that arise from multiple pathways to block AGE formation and prevent its interaction with RAGE.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Dariya B,Nagaraju GP

doi

10.1016/j.drudis.2020.07.003

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

1614-1623

issue

9

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(20)30262-2

journal_volume

25

pub_type

杂志文章,评审
  • Mining the GEMS--a novel platform technology targeting post-transcriptional control mechanisms.

    abstract::The physiological levels of many clinically important proteins are regulated through cellular mechanisms that control the stability and translational efficiency of mRNA. These post-transcriptional processes, which play a critical role in the regulation of gene expression, depend on interactions of specific trans-actin...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.05.009

    authors: Bhattacharyya A,Trotta CR,Peltz SW

    更新日期:2007-07-01 00:00:00

  • Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?

    abstract::Options for disease-modifying therapies in multiple sclerosis have increased over the past two decades. Among these innovations are interferon-β, glatiramer acetate, fumaric acid and dihydroorotate dehydrogenase inhibitors, an antibody targeting the migration of immune cells, a compound that traps immune cells in lymp...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.11.022

    authors: Findling O,Sellner J

    更新日期:2020-11-25 00:00:00

  • 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments.

    abstract::Gene expression microarrays have been used widely to address increasingly complex biological questions and to produce an unprecedented amount of data, but have yet to realize their full potential. The interpretation of microarray data remains a major challenge because of the complexity of the underlying biological net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03565-8

    authors: Imbeaud S,Auffray C

    更新日期:2005-09-01 00:00:00

  • Bioscience industry in metro Atlanta.

    abstract::One of the world's fastest growing cities, Atlanta is the business center of the Southeast U.S. and is rapidly becoming a leader for biotechnology innovation. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03374-X

    authors: Allen CR

    更新日期:2005-02-15 00:00:00

  • E-drug delivery: a futuristic approach.

    abstract::Drug delivery systems are undergoing technology changes to enhance patient comfort and compliance. Electronic drug delivery (E-drug delivery) systems are being developed to regulate drug dose delivery by easy monitoring of doses, especially in chronic and age-related diseases. E-drug delivery can monitor the correct d...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.02.005

    authors: Yadav KS,Kapse-Mistry S,Peters GJ,Mayur YC

    更新日期:2019-04-01 00:00:00

  • Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases.

    abstract::Fatty acid amide hydrolase (FAAH) is responsible for the hydrolysis of several important endogenous fatty acid amides (FAAs), including anandamide, oleoylethanolamide and palmitoylethanolamide. Because specific FAAs interact with cannabinoid and vanilloid receptors, they are often referred to as 'endocannabinoids' or ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.08.002

    authors: Pillarisetti S,Alexander CW,Khanna I

    更新日期:2009-12-01 00:00:00

  • Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.

    abstract::Although the 5-hydroxytryptamine(6) (5-HT(6)) receptor was discovered only recently, its almost exclusive distribution in the brain makes it a promising, novel, target for central nervous system (CNS)-mediated diseases such as Alzheimer's disease (cognitive function), schizophrenia, anxiety and obesity. In the past fe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.02.004

    authors: Holenz J,Pauwels PJ,Díaz JL,Mercè R,Codony X,Buschmann H

    更新日期:2006-04-01 00:00:00

  • HCV E2 core structures and mAbs: something is still missing.

    abstract::The lack of structural information on hepatitis C virus (HCV) surface proteins has so far hampered the development of effective vaccines. Recently, two crystallographic structures have described the core portion (E2c) of E2 surface glycoprotein, the primary mediator of HCV entry. Despite the importance of these studie...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.08.011

    authors: Castelli M,Clementi N,Sautto GA,Pfaff J,Kahle KM,Barnes T,Doranz BJ,Dal Peraro M,Clementi M,Burioni R,Mancini N

    更新日期:2014-12-01 00:00:00

  • The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

    abstract::Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical research today. Translational PK-PD has the ability to integrate data generated from diverse test platforms during discovery and development in a mechanistic framework. Therefore, successful implementation of translati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.10.002

    authors: Agoram BM,Martin SW,van der Graaf PH

    更新日期:2007-12-01 00:00:00

  • Precision medicine in oncology drug development: a pharma perspective.

    abstract::A rapid expansion in precision medicine founded on the potential for durable clinical benefit through matching a drug to a predictive marker used to select patients has driven the development of targeted drugs with accompanied companion diagnostics for patient selection. Oncology has been at the forefront, with the im...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.10.005

    authors: Hollingsworth SJ

    更新日期:2015-12-01 00:00:00

  • Humans are animals, but are animals human enough? A systematic review and meta-analysis on interspecies differences in renal drug clearance.

    abstract::Various animal models are used to study pharmacokinetics (PK) of drugs in development. Human renal clearance (CLr) should be predictable through interpolation from animal data by allometric scaling. Based on this premise, we quantified interspecies differences in CLr, and related them to drug properties. Using PubMed ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.01.018

    authors: Jansen K,Pou Casellas C,Groenink L,Wever KE,Masereeuw R

    更新日期:2020-04-01 00:00:00

  • Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

    abstract::The identification of two biologically active fatty acid amides, N-arachidonoylethanolamine (anandamide) and oleamide, has generated a great deal of excitement and stimulated considerable research. However, anandamide and oleamide are merely the best-known and best-understood members of a much larger family of biologi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.02.006

    authors: Farrell EK,Merkler DJ

    更新日期:2008-07-01 00:00:00

  • Understanding the checkpoint blockade in lung cancer immunotherapy.

    abstract::Immunotherapies have changed the treatment strategy of some types of tumor including melanoma and, more recently, non-small-cell lung cancer (NSCLC). Immune checkpoints are crucial for the maintenance of self-tolerance and it is known that some tumors use checkpoint systems to evade antitumor immune response. The trea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.05.016

    authors: Dal Bello MG,Alama A,Coco S,Vanni I,Grossi F

    更新日期:2017-08-01 00:00:00

  • Translational strategies for development of monoclonal antibodies from discovery to the clinic.

    abstract::Successful strategies for the development of monoclonal antibodies require integration of knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, Fc domain engineering, PK/PD properties and antibody cross-reactivity across species from the early stages of anti...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.12.008

    authors: Tabrizi MA,Bornstein GG,Klakamp SL,Drake A,Knight R,Roskos L

    更新日期:2009-03-01 00:00:00

  • Expanding medicinal chemistry space.

    abstract::Clinically useful drugs target a relatively small number of proteins that lie within a clearly defined and chemically accessible space. However, many high value biological targets lie outside this chemical space, and an ability to access such 'intractable' targets not amenable to traditional small molecule interventio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.10.008

    authors: Barker A,Kettle JG,Nowak T,Pease JE

    更新日期:2013-03-01 00:00:00

  • A novel approach to identifying antiarrhythmic drug targets.

    abstract::Sudden cardiac death, secondary to ventricular fibrillation (VF), remains the leading cause of death in the USA. Recent experimental and theoretical studies suggest that VF could be caused by spiral wave re-entry. The initiation and subsequent break-up of spiral waves has been linked to electrical alternans, a phenome...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02567-9

    authors: Gilmour RF Jr

    更新日期:2003-02-15 00:00:00

  • How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.

    abstract::The current understanding of the pathology that underlies pulmonary vascular and right ventricular remodeling in pulmonary hypertension is discussed. Although recent studies underscored the importance of intima and media remodeling and, for the first time, the relevance of perivascular inflammation, much is needed to ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.05.022

    authors: Tuder RM

    更新日期:2014-08-01 00:00:00

  • Timely synthetic support for medicinal chemists.

    abstract::In recent years, there have been significant developments made in the way new drugs are being discovered and developed. Such changes are driven by new technologies that have expanded the opportunities to prepare and screen large libraries of compounds in a rapid time frame by the use of high-throughput synthesis and s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03298-2

    authors: Potoski J

    更新日期:2005-01-15 00:00:00

  • Use of Benford's law in drug discovery data.

    abstract::Benford's law states that the distribution of the first digit of many data sets is not uniform. The first digit of any random number will be 1 almost 30% of the time, and larger digits occur as the first digit with lower and lower frequency, to the point where 9 occurs as a first digit only 5% of the time. Here, we de...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2010.03.003

    authors: Orita M,Moritomo A,Niimi T,Ohno K

    更新日期:2010-05-01 00:00:00

  • Monoclonal antibodies for chronic refractory asthma and pipeline developments.

    abstract::Patients with severe asthma suffer persistent symptoms and/or frequent exacerbations despite high-intensity treatment. Their severe unrelenting symptoms have a huge impact on healthcare resources owing to frequent hospital admissions and requirement for intensive treatments. Consequently, there is an undeniable need f...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.01.012

    authors: Polosa R,Casale T

    更新日期:2012-06-01 00:00:00

  • WITHDRAWN: Enabling infrastructure for global health product development.

    abstract::This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.05.014

    authors: Satcher R,Evans-Storms RB

    更新日期:2012-06-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Gestational hypoxia and epigenetic programming of brain development disorders.

    abstract::Adverse environmental conditions faced by an individual early during its life, such as gestational hypoxia, can have a profound influence on the risk of diseases, such as neurological disorders, in later life. Clinical and preclinical studies suggest that epigenetic programming of gene expression patterns in response ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.09.010

    authors: Ma Q,Xiong F,Zhang L

    更新日期:2014-12-01 00:00:00

  • Is the oral route possible for peptide and protein drug delivery?

    abstract::Oral delivery of peptides and proteins remains an attractive alternative to parenteral delivery and has challenged various attempts at delivery development. Incorporation of new tools into the delivery systems that can raise membrane permeability of macromolecules is essential to attain high oral bioavailability that ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.08.005

    authors: Morishita M,Peppas NA

    更新日期:2006-10-01 00:00:00

  • pH-dependent ileocolonic drug delivery, part I: in vitro and clinical evaluation of novel systems.

    abstract::After the pH dependency of novel pH-dependent ileocolonic drug delivery systems is confirmed in vitro, their performance should be evaluated in human volunteers. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.06.011

    authors: Broesder A,Woerdenbag HJ,Prins GH,Nguyen DN,Frijlink HW,Hinrichs WLJ

    更新日期:2020-08-01 00:00:00

  • 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.

    abstract::Carcinomas overexpressing EGFR family receptors are of high clinical importance, because the receptors have prognostic value and are used as molecular targets for anticancer therapy. Insufficient drug efficacy necessitates further in-depth research of the receptor biology and improvement in preclinical stages of drug ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.003

    authors: Sokolova EA,Vodeneev VA,Deyev SM,Balalaeva IV

    更新日期:2019-01-01 00:00:00

  • Microarray patches: potentially useful delivery systems for long-acting nanosuspensions.

    abstract::Long-acting drug nanosuspension formulations are coming to the fore as controlled release strategies for several medical conditions and as a preventative measure against HIV infection. However, such delivery systems must, by necessity, be given by hypodermic injection, typically into muscle. This poses problems for pa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.013

    authors: Donnelly RF,Larrañeta E

    更新日期:2018-05-01 00:00:00

  • Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.

    abstract::Current advances in systems biology suggest a new change of paradigm reinforcing the holistic nature of the drug discovery process. According to the principles of systems biology, a simple drug perturbing a network of targets can trigger complex reactions. Therefore, it is possible to connect initial events with final...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.02.004

    authors: Cruz-Monteagudo M,Schürer S,Tejera E,Pérez-Castillo Y,Medina-Franco JL,Sánchez-Rodríguez A,Borges F

    更新日期:2017-07-01 00:00:00

  • Advances in the computational development of DNA methyltransferase inhibitors.

    abstract::DNA methylation is an epigenetic change that results in the addition of a methyl group at the carbon-5 position of cytosine residues. The process is mediated by DNA methyltransferases (DNMTs), a family of enzymes for which inhibition is a promising strategy for the treatment of cancer and other diseases. Here, we revi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.02.003

    authors: Medina-Franco JL,Caulfield T

    更新日期:2011-05-01 00:00:00

  • The TNF superfamily is on the TRAIL to BlyS.

    abstract::Highlights of the 9th (Biennial) International Congress on TNF-Related Cytokines (30 October-2 November 2002; The Manchester Grand Hyatt, San Diego, CA, USA. ...

    journal_title:Drug discovery today

    pub_type:

    doi:10.1016/s1359-6446(02)02592-8

    authors: Steed PM,Hubert RS

    更新日期:2003-02-01 00:00:00